Your browser doesn't support javascript.
loading
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
Pflug, Natali; Cramer, Paula; Robrecht, Sandra; Bahlo, Jasmin; Westermann, Anne; Fink, Anna-Maria; Schrader, Alexandra; Mayer, Petra; Oberbeck, Sebastian; Seiler, Till; Zenz, Thorsten; Dürig, Jan; Kreuzer, Karl-Anton; Stilgenbauer, Stephan; Eichhorst, Barbara; Hallek, Michael; Herling, Marco; Hopfinger, Georg.
Afiliação
  • Pflug N; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Cramer P; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Robrecht S; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Bahlo J; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Westermann A; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Fink AM; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Schrader A; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Mayer P; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Oberbeck S; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Seiler T; b Medizinische Klinik und Poliklinik III , LMU University of Munich , Munich , Germany.
  • Zenz T; c National Center for Tumor Diseases Heidelberg , Heidelberg , Germany.
  • Dürig J; d Klinik für Hämatologie , University of Essen , Essen , Germany.
  • Kreuzer KA; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Stilgenbauer S; e Department of Internal Medicine III , University of Ulm , Ulm , Germany.
  • Eichhorst B; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Hallek M; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Herling M; a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC) , University of Cologne , Cologne , Germany.
  • Hopfinger G; f AKH Wien , Universitätsklinik für Innere Medizin I , Vienna , Austria.
Leuk Lymphoma ; 60(3): 649-657, 2019 03.
Article em En | MEDLINE | ID: mdl-30234404
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Prolinfocítica de Células T / Protocolos de Quimioterapia Combinada Antineoplásica / Alemtuzumab Tipo de estudo: Clinical_trials / Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Prolinfocítica de Células T / Protocolos de Quimioterapia Combinada Antineoplásica / Alemtuzumab Tipo de estudo: Clinical_trials / Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article